High-Throughput Screening in Traditional Chinese Medicine-Based Drug Discovery



Traditional Chinese medicine (TCM) has demonstrated its effectiveness in the treatment of ailments and diseases over a long history of application, but its wider acceptance has been hindered by a lack of scientific evidence for efficacy and safety as well as a barrier of languages and cultures. In the 1990s, biotech and pharmaceutical companies have started to take interest in traditional medicines in their efforts to replenish the drying pipelines, yet the results were not sufficiently impressive to warrant extensive attention. Recently, along with the rapid advancements in biology and new technologies, there is a resurgent interest in the potential of the ancient medicine. Given our proximity to the Chinese mainland, our institute has utilized TCM as a source of potential drug candidates as well as a probe for understanding complex signaling pathways. This chapter describes the application of a number of versatile high throughput techniques for identifying therapeutic agents from TCM preparations. The rationale and principles for each approach will be discussed and illustrated with examples.


Traditional Chinese Medicine Traditional Chinese Medicine Formula Brain Endothelial Cell Line Traditional Chinese Medicine Preparation Complex Traditional Chinese Medicine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Support for the work came from the Innovation and Technology Fund (AF/178/97, AF/166/99, ITS/119/00, ITS/113/03), the University Grants Committee (AoE/B-15/01, AoE/B-15/01-II, T13-607/12R and HKUST 660108), the Hong Kong Jockey Club Charities Trust, and Geron Corporation.


  1. 1.
    Kitano H (2002) Computational systems biology. Nature 420:206–210PubMedCrossRefGoogle Scholar
  2. 2.
    Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, van der Heijden R, Voshol PJ, Havekes LM, Verpoorte R, van der Greef J (2005) Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother res 19:173–182PubMedCrossRefGoogle Scholar
  3. 3.
    Chen X, Zhou H, Liu YB, Wang JF, Li H, Ung CY, Han LY, Cao ZW, Chen YZ (2006) Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Br J Pharmacol 149:1092–1103PubMedCrossRefGoogle Scholar
  4. 4.
    Wang Y, Fan X, Qu H, Gao X, Cheng Y (2012) Strategies and techniques for multi-component drug design from medicinal herbs and traditional chinese medicine. Curr Top Med Chem 12:1356–1362PubMedCrossRefGoogle Scholar
  5. 5.
    Li WF, Jiang JG, Chen J (2008) Chinese medicine and its modernization demands. Arch Med Res 39:246–251PubMedCrossRefGoogle Scholar
  6. 6.
    Tu Y (2011) The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 17:1217–1220PubMedCrossRefGoogle Scholar
  7. 7.
    Miller LH, Su X (2011) Artemisinin: discovery from the Chinese herbal garden. Cell 146:855–858PubMedCrossRefGoogle Scholar
  8. 8.
    Graziose R, Lila MA, Raskin I (2010) Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr Drug Discov Technol 7:2–12PubMedCrossRefGoogle Scholar
  9. 9.
    Tian S, Wang J, Li Y, Xu X, Hou T (2012) Drug-likeness analysis of traditional Chinese medicines: 3. Prediction of drug-likeness using machine learning approaches. Mol Pharm PMID 22738405Google Scholar
  10. 10.
    May BH, Lu C, Bennett L, Hügel HM, Xue CC (2012) Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for age-related dementia and memory impairment. Biogerontology 13:299–312PubMedCrossRefGoogle Scholar
  11. 11.
    Fu GM, Pang H, Wong YH (2008) Naturally occurring phenylethanoid glycosides: potential leads for new therapeutics. Curr Med Chem 15:2592–2613PubMedCrossRefGoogle Scholar
  12. 12.
    Li XJ, Kong DX, Zhang HY (2010) Chemoinformatics approaches for traditional Chinese medicine research and case application in anticancer drug discovery. Curr Drug Discov Technol 7:22–31PubMedCrossRefGoogle Scholar
  13. 13.
    Barlow DJ, Buriani A, Ehrman T, Bosisio E, Eberini I, Hylands PJ (2012) In-silico studies in Chinese herbal medicines’ research: evaluation of in silico methodologies and phytochemical data sources, and a review of research to date. J Ethnopharmacol 140:526–534PubMedCrossRefGoogle Scholar
  14. 14.
    Ho YS, So KF, Chang RC (2011) Drug discovery from Chinese medicine against neurodegeneration in Alzheimer’s and vascular dementia. Chin Med 6:15Google Scholar
  15. 15.
    Gashaw I, Ellinghaus P, Sommer A, Asadullah K (2011) What makes a good drug target? Drug Discov Today 16:1037–1043PubMedCrossRefGoogle Scholar
  16. 16.
    Sun X, Chan LN, Gong X, Sucher NJ (2003) N-methyl-D-aspartate receptor antagonist activity in traditional Chinese stroke medicines. Neurosignals 12:31–38PubMedCrossRefGoogle Scholar
  17. 17.
    Sucher NJ (2006) Insights from molecular investigations of traditional Chinese herbal stroke medicines: implications for neuroprotective epilepsy therapy. Epilepsy Behav 8:350–362PubMedCrossRefGoogle Scholar
  18. 18.
    Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazana J, Hylands PJ (2012) Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol 140:535–544PubMedCrossRefGoogle Scholar
  19. 19.
    Sun H, Zhang A, Wang X (2012) Potential role of metabolomic approaches for chinese medicine syndromes and herbal medicine. Phytother Res 26:1466–1471PubMedCrossRefGoogle Scholar
  20. 20.
    Knowles J, Gromo G (2003) A guide to drug discovery: Target selection in drug discovery. Nat Rev Drug Discov 2:63–69PubMedCrossRefGoogle Scholar
  21. 21.
    Global Industry Analysts Inc (2012) World market for G-protein-coupled receptors (GPCRs) targeting drugs to reach US$120.5 billion by 2017. http://www.strategyr.com/pressMCP-6269.asp. Accessed 20 Apr 2012
  22. 22.
    Liu AM, Ho MK, Wong CS, Chan JH, Pau AH, Wong YH (2003) Gα16/z chimeras efficiently link a wide range of G protein-coupled receptors to calcium mobilization. J Biomol Screen 8:39–49PubMedCrossRefGoogle Scholar
  23. 23.
    New DC, Wong YH (2004) Characterization of CHO cells stably expressing a Gα16/z chimera for high-throughput screening of GPCRs. Assay Drug Dev Technol 2:269–280PubMedCrossRefGoogle Scholar
  24. 24.
    New DC, Wong YH (2005) Chimeric and promiscuous G proteins in drug discovery and the deorphanization of GPCRs. Drug Design Rev Online 2:66–79CrossRefGoogle Scholar
  25. 25.
    New DC, Miller-Martini DM, Wong YH (2003) Reporter gene assays and their applications to bioassays of natural products. Phytother Res 17:439–448PubMedCrossRefGoogle Scholar
  26. 26.
    Liu AM, New DC, Lo RK, Wong YH (2009) Reporter gene assays. Methods Mol Biol 486:109–123PubMedCrossRefGoogle Scholar
  27. 27.
    Miller-Martini DM, Chan RY, Ip NY, Sheu SJ, Wong YH (2001) A reporter gene assay for the detection of phytoestrogens in traditional Chinese medicine. Phytother Res 15:487–492PubMedCrossRefGoogle Scholar
  28. 28.
    Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC, Tong Y, Zhang YB (2012) Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 139:698–711PubMedCrossRefGoogle Scholar
  29. 29.
    Stahl SM (2000) The new cholinesterase inhibitors for Alzheimer’s disease, Part 2: illustrating their mechanisms of action. J Clin Psychiatry 61:813–814PubMedCrossRefGoogle Scholar
  30. 30.
    Correll PH, Morrison AC, Lutz MA (2004) Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol 75:731–737PubMedCrossRefGoogle Scholar
  31. 31.
    Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD (1998) Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J 17:1740–1749PubMedCrossRefGoogle Scholar
  32. 32.
    Chan AS, Yip EC, Yung LY, Pang H, Luk SC, Pang SF, Wong YH (2005) Immuo-regulatory effects of CKBM on the activities of mitogen-activated protein kinases and the release of cytokines in THP-1 monocytic cells. Biol Pharm Bull 28:1645–1650PubMedCrossRefGoogle Scholar
  33. 33.
    Chan AS, Yip EC, Yung LY, Pang H, Luk SC, Pang SF, Wong YH (2006) CKBM stimulates MAPKs but inhibits LPS-induced INF-γ production in lymphocytes. Phytother Res 20:725–731PubMedCrossRefGoogle Scholar
  34. 34.
    Chan ASL, Pang H, Yip ECH, Tam YK, Wong YH (2006) The aqueous extract of Radix Glycyrrhizae stimulates mitogen-activated protein kinases and nuclear factor-κB in Jurkat T-cells and THP-1 monocytic cells. Am J Chin Med 34:263–278PubMedCrossRefGoogle Scholar
  35. 35.
    Chan AS, Pang H, Yip EC, Tam YK, Wong YH (2005) Carvacrol and eugenol differentially stimulate intracellular Ca2+ mobilization and mitogen-activated protein kinases in Jurkat T-cells and monocytic THP-1 cells. Planta Med 71:634–639PubMedCrossRefGoogle Scholar
  36. 36.
    Yip EC, Liu AM, Wong JT, Wong YH (2005) An aqueous extract of the popular Chinese nutraceutic Kwek Ling Ko (Tortoise shell-Rhzoma Jelly) activates the PPARγ pathway and down-regulates the NFκB activity. Phytomedicine 12:748–759PubMedCrossRefGoogle Scholar
  37. 37.
    Schoonen WG, Westerink WM, de Roos JA, Débiton E (2005) Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol In Vitro 19:505–516PubMedCrossRefGoogle Scholar
  38. 38.
    Schoonen WG, de Roos JA, Westerink WM, Débiton E (2005) Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 19:491–503PubMedCrossRefGoogle Scholar
  39. 39.
    Miret S, De Groene EM, Klaffke W (2006) Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J Biomol Screen 11:184–193PubMedCrossRefGoogle Scholar
  40. 40.
    Ansorena E, García-Trevijano ER, Martínez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC, Avila MA (2002) S-Adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 35:274–280PubMedCrossRefGoogle Scholar
  41. 41.
    Sun D, Gong Y, Kojima H, Wang G, Ravinsky E, Zhang M, Minuk GY (2003) Increasing cell membrane potential and GABAergic activity inhibits malignant hepatocyte growth. Am J Physiol Gastrointest Liver Physiol 285:G12–G19PubMedGoogle Scholar
  42. 42.
    Ichijo H (1999) From receptors to stress-activated MAP kinases. Oncogene 18:6087–6093PubMedCrossRefGoogle Scholar
  43. 43.
    Harper SJ, LoGrasso P (2001) Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal 13:299–310PubMedCrossRefGoogle Scholar
  44. 44.
    Yip EC, Chan AS, Pang H, Tam YK, Wong YH (2006) Protocatechuic acid induces cell death in HepG2 hepatocellular carcinoma cells through a c-Jun N-terminal kinase-dependent mechanism. Cell Biol Toxicol 22:293–302PubMedCrossRefGoogle Scholar
  45. 45.
    Wang X, Sun H, Zhang A, Jiao G, Sun W, Yuan Y (2011) Pharmacokinetics screening for multi-components absorbed in the rat plasma after oral administration traditional Chinese medicine formula Yin-Chen-Hao-Tang by ultra performance liquid chromatography-electrospray ionization/quadrupole-time-of-flight mass spectrometry combined with pattern recognition methods. Analyst 136:5068–5076PubMedCrossRefGoogle Scholar
  46. 46.
    Zhu J, Lee S, Ho MK, Hu Y, Pang H, Ip FC, Chin AC, Harley CB, Ip NY, Wong YH (2010) In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator. Drug Metab Pharmacokinet 25:477–486PubMedCrossRefGoogle Scholar
  47. 47.
    Zhu J, Hu Y, Ho MK, Wong YH (2011) 3-methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties. Xenobiotica 41:35–45PubMedCrossRefGoogle Scholar
  48. 48.
    Zhu J, Hu Y, Ho MK, Wong YH (2012) Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats. Xenobiotica 42:1138–1150PubMedCrossRefGoogle Scholar
  49. 49.
    Prieto P, Blaauboer BJ, de Boer AG, Boveri M, Cecchelli R, Clemedson C, Coecke S, Forsby A, Galla HJ, Garberg P, Greenwood J, Price A, Tähti H (2004) European centre for the validation of alternative methods blood-brain barrier in vitro models and their application in toxicology. The report and recommendations of ECVAM Workshop 49. Altern Lab Anim 32:37–50Google Scholar
  50. 50.
    Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 71:113–128Google Scholar
  51. 51.
    Mody SM, Hu Y, Ho MK, Wong YH (2007) In search of novel and therapeutically significant melatoninergic ligands. Recent Pat CNS Drug Discov 2:241–245PubMedCrossRefGoogle Scholar
  52. 52.
    Hu Y, Ho MK, Chan KH, New DC, Wong YH (2010) Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT2-selective melatonin ligands. Bioorg Med Chem Lett 20:2582–2585PubMedCrossRefGoogle Scholar
  53. 53.
    Granger MP, Wright WE, Shay JW (2002) Telomerase in cancer and aging. Crit Rev Oncol Hematol 41:29–40PubMedCrossRefGoogle Scholar
  54. 54.
    Funk WD, Wang CK, Shelton DN, Harley CB, Pagon GD, Hoeffler WK (2000) Telomerase expression restores dermal integrity to in vitro-aged fibroblasts in a reconstituted skin model. Exp Cell Res 258:270–278PubMedCrossRefGoogle Scholar
  55. 55.
    Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA (2000) Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 287:1253–1258PubMedCrossRefGoogle Scholar
  56. 56.
    Dagarag M, Ng H, Lubong R, Effros RB, Yang OO (2003) Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol 77:3077–3083PubMedCrossRefGoogle Scholar
  57. 57.
    Gu X, Zhang J, Brann DW, Yu FS (2003) Brain and retinal vascular endothelial cells with extended life span established by ectopic expression of telomerase. Invest Ophthalmol Vis Sci 44:3219–3225PubMedCrossRefGoogle Scholar
  58. 58.
    Roy NS, Nakano T (2004) Telomerase immortalization of neuronally restricted progenitor cells derived from the human fetal spinal cord. Nat Biotechnol 22:297–305PubMedCrossRefGoogle Scholar
  59. 59.
    Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, Hooijberg E, Schumacher TN, Haanen JB, Spits H, Luiten RM (2004) Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res 64:2153–2161PubMedCrossRefGoogle Scholar
  60. 60.
    Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB, Effros RB (2008) Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol 181:7400–7406PubMedGoogle Scholar
  61. 61.
    Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, Pang H, Chin AC, Harley CB, Ip NY, Wong YH (2012) Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types. Planta Med 78:115–121PubMedCrossRefGoogle Scholar
  62. 62.
    Pammolli F, Magazzini L, Riccaboni M (2011) The productivity in pharmaceutical R&D. Nat Rev Drug Discov 10:428–438PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Biotechnology Research Institute and Division of Life ScienceHong Kong University of Science and TechnologyKowloon, Hong KongChina
  2. 2.Division of Life ScienceState Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and TechnologyKowloon, Hong Kong China

Personalised recommendations